E
Description
Gastroenterology specialty pharmaceutical company founded in 2020 in Blue Bell, PA, by TPG Capital. Develops APT-1011 (Phase 3) for eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus. Backed by Marshall Wace and TPG with $40M.